ASH 2017: CTL019 Produces High 6-Month Response Rates in Highly Pretreated Adult Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Only registered members have full access to PracticeUpdate content.